Feature|Articles|September 11, 2023

Pharmaceutical Executive

  • Pharmaceutical Executive: September 2023
  • Volume 43
  • Issue 9

Ahead of the Curve: Pharm Exec Profiles Five Recent Drug Launches

Pharm Exec’s latest selections of notable biopharma brand launches—some with novel preemptive approaches—highlight products that are paving uncharted paths across a diverse disease landscape.

Follow the links below to read about each product:

Camzyos (Bristol Myers Squibb)

Enhertu (Daiichi Sankyo, AstraZeneca)

Rebyota (Ferring Pharmaceuticals)

Sunlenca (Gilead Sciences)

Tzield (Provention Bio, a Sanofi company)

Selections were made by Pharmaceutical Executive's editorial staff, with close input from Editorial Advisory Board members.

Articles in this issue

about 2 years ago

A New Era of Ethical Leadership

about 2 years ago

Survival Story: Enhertu

about 2 years ago

Gut Instinct: Rebyota

about 2 years ago

Delaying Disease Onset: Tzield

about 2 years ago

New Beginnings: Sunlenca

about 2 years ago

A Heartfelt Solution: Camzyos

about 2 years ago

Fortifying Defenses Pre-Patent Cliff

about 2 years ago

No Rate Relief in Sight for Biotech

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.